Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb 6;17(2):224.
doi: 10.3390/ijms17020224.

Hepatotoxicity by Drugs: The Most Common Implicated Agents

Einar S Björnsson  1
Affiliations
Review

Hepatotoxicity by Drugs: The Most Common Implicated Agents

Einar S Björnsson. Int J Mol Sci. .

Abstract

Idiosyncratic drug-induced liver injury (DILI) is an underreported and underestimated adverse drug reaction. Information on the documented hepatotoxicity of drugs has recently been made available by a website that can be accessed in the public domain: LiverTox (http://livertox.nlm.nih.gov). According to critical analysis of the hepatotoxicity of drugs in LiverTox, 53% of drugs had at least one case report of convincing reports of liver injury. Only 48 drugs had more than 50 case reports of DILI. Amoxicillin-clavulanate is the most commonly implicated agent leading to DILI in the prospective series. In a recent prospective study, liver injury due to amoxicillin-clavulanate was found to occur in approximately one out of 2300 users. Drugs with the highest risk of DILI in this study were azathioprine and infliximab.

Keywords: drug-induced liver injury; drugs; hepatotoxicity; idiosyncratic.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. European Medicines Agency. [(accessed on 1 May 2015)]. Available online: http://www.ema.europa.eu.
    1. Physician Desk Reference (PDR) [(accessed on 1 May 2015)]. Available online: http://www.pdr.net.
    1. Bjornsson E.S., Jacobsen E.I., Einarsdottir R., Chalasani N. Discrepancies in liver disease labeling in the package inserts of commonly prescribed medications. Gastroenterology. 2015;148:269–273. doi: 10.1053/j.gastro.2014.12.007. - DOI - PubMed
    1. Andrade R.J., Robles M., Lucena M.I. Rechallenge in drug-induced liver injury: The attractive hazard. Expert Opin. Drug Saf. 2009;8:709–714. doi: 10.1517/14740330903397378. - DOI - PubMed
    1. Papay J.I., Clines D., Rafi R., Yuen N., Britt S.D., Walsh J.S., Hunt C.M. Drug-induced liver injury following positive drug rechallenge. Regul. Toxicol. Pharmacol. 2009;54:84–90. doi: 10.1016/j.yrtph.2009.03.003. - DOI - PubMed

MeSH terms

Substances